Hannah Priyadarshini Gideon

Hannah Priyadarshini Gideon

Auto-generated profile, based on publicly available information

Hannah Priyadarshini Gideon

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
HGHannah Priyadarshini Gideon
Hannah Priyadarshini Gideon
JPJiaYao Phuah
JiaYao Phuah
AMAmy J Myers
Amy J Myers
BBBryan D Bryson
Bryan D Bryson
MRMark A Rodgers
Mark A Rodgers
JFJoAnne L Flynn
JoAnne L Flynn
Lung granulomas are the pathologic hallmark of tuberculosis (TB). T cells are a major cellular component of TB lung granulomas and are known to play an important role in containment of Mycobacterium tuberculosis (Mtb) infection. We used cynomolgus macaques, a non-human primate model that recapitulates human TB with clinically active disease, latent infection or early infection, to understand functional characteristics and dynamics of T cells in individual granulomas. We sought to correlate T cell cytokine response and bacterial burden of each granuloma, as well as granuloma and systemic responses in individual animals. Our results support that each granuloma within an individual host is independent with respect to total cell numbers, proportion of T cells, pattern of cytokine response, and bacterial burden. The spectrum of these components overlaps greatly amongst animals with different clinical status, indicating that a diversity of granulomas exists within an individual host. On average only about 8% of T cells from granulomas respond with cytokine production after stimulation with Mtb specific antigens, and few “multi-functional” T cells were observed. However, granulomas were found to be “multi-functional” with respect to the combinations of functional T cells that were identified among lesions from individual animals. Although the responses generally overlapped, sterile granulomas had modestly higher frequencies of T cells making IL-17, TNF and any of T-1 (IFN-γ, IL-2, or TNF) and/or T-17 (IL-17) cytokines than non-sterile granulomas. An inverse correlation was observed between bacterial burden with TNF and T-1/T-17 responses in individual granulomas, and a combinatorial analysis of pair-wise cytokine responses indicated that granulomas with T cells producing both pro- and anti-inflammatory cytokines (e.g. IL-10 and IL-17) were associated with clearance of Mtb. Preliminary evaluation suggests that systemic responses in the blood do not accurately reflect local T cell responses within granulomas. The characteristic feature of Mycobacterium tuberculosis (Mtb) infection is the formation of lesions, which are organized structures of immune cells in the lungs called granulomas, which contain the bacteria. When the granuloma functions effectively, it can kill the bacteria. T cells (a type of immune cell, also present in granulomas) are known to play an important role in control of tuberculosis. However, functions of T cells at individual granuloma levels are unknown. Here, we studied the functional characteristics of T cells, which are defined by the production of chemical messengers (cytokines) at the granuloma level in a non-human primate model. We compared the relationship between cytokine response and the number of bacteria (Mtb) in each granuloma. Each granuloma was found to be unique, suggesting different types exist within an animal. Only a small proportion of T cells produced any cytokine, but different types of cytokines were observed within each granuloma. A balance between different types of cytokine was associated with more killing of bacteria in granulomas. Understanding how to improve the T cell responses to obtain killing of bacteria in the granuloma will be important for vaccine development.

3 January 2012 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
PLPhilana Ling Lin
Philana Ling Lin
JDJes Dietrich
Jes Dietrich
ETEsterlina Tan
Esterlina Tan
RARodolfo M. Abalos
Rodolfo M. Abalos
JBJasmin Burgos
Jasmin Burgos
PAPeter Andersen
Peter Andersen
It is estimated that one-third of the world’s population is infected with Mycobacterium tuberculosis. Infection typically remains latent, but it can reactivate to cause clinical disease. The only vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is largely ineffective, and ways to enhance its efficacy are being developed. Of note, the candidate booster vaccines currently under clinical development have been designed to improve BCG efficacy but not prevent reactivation of latent infection. Here, we demonstrate that administering a multistage vaccine that we term H56 in the adjuvant IC31 as a boost to vaccination with BCG delays and reduces clinical disease in cynomolgus macaques challenged with M. tuberculosis and prevents reactivation of latent infection. H56 contains Ag85B and ESAT-6, which are two of the M. tuberculosis antigens secreted in the acute phase of infection, and the nutrient stress–induced antigen Rv2660c. Boosting with H56/IC31 resulted in efficient containment of M. tuberculosis infection and reduced rates of clinical disease, as measured by clinical parameters, inflammatory markers, and improved survival of the animals compared with BCG alone. Boosted animals showed reduced pulmonary pathology and extrapulmonary dissemination, and protection correlated with a strong recall response against ESAT-6 and Rv2660c. Importantly, BCG/H56-vaccinated monkeys did not reactivate latent infection after treatment with anti-TNF antibody. Our results indicate that H56/IC31 boosting is able to control late-stage infection with M. tuberculosis and contain latent tuberculosis, providing a rationale for the clinical development of H56.

1 May 2009 in Trends in Microbiology
Verified
Journal Article
Closed access
DYDouglas B. Young
Douglas B. Young
HGHannah P. Gideon
Hannah P. Gideon
RWRobert J. Wilkinson
Robert J. Wilkinson

20 February 2015 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
JFJoAnne L. Flynn
JoAnne L. Flynn
HGHannah P. Gideon
Hannah P. Gideon
JMJoshua T. Mattila
Joshua T. Mattila
PLPhilana Ling Lin
Philana Ling Lin

30 June 2011 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
HGHannah P. Gideon
Hannah P. Gideon
JFJoAnne L. Flynn
JoAnne L. Flynn

22 November 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
EIEdward B. Irvine
Edward B. Irvine
AOAnthony O’nEil
Anthony O’nEil
PDPatricia A. Darrah
Patricia A. Darrah
SSSally Shin
Sally Shin
CAChoudhary Alok
Choudhary Alok
GAGalit Alter
Galit Alter
Development of an effective tuberculosis (TB) vaccine has suffered from an incomplete understanding of the correlates of protection againstMycobacterium tuberculosis(Mtb). Intravenous (i.v.) vaccination with Bacille Calmette–Guérin (BCG) provides nearly complete protection against TB in rhesus macaques, but the antibody response it elicits remains incompletely defined. Here we show that i.v. BCG drives superior antibody responses in the plasma and the lungs of rhesus macaques compared to traditional intradermal BCG administration. While i.v. BCG broadly expands antibody titers and functions, IgM titers in the plasma and lungs of immunized macaques are among the strongest markers of reduced bacterial burden. IgM was also enriched in macaques that received protective vaccination with an attenuated strain ofMtb. Finally, anMtb-specific IgM monoclonal antibody reducedMtbsurvival in vitro. Collectively, these data highlight the potential importance of IgM responses as a marker and mediator of protection against TB.